annual FCF:
-$4.05B-$230.00M(-6.01%)Summary
- As of today (May 21, 2025), MRNA annual free cash flow is -$4.05 billion, with the most recent change of -$230.00 million (-6.01%) on December 31, 2024.
- During the last 3 years, MRNA annual FCF has fallen by -$17.39 billion (-130.41%).
- MRNA annual FCF is now -130.41% below its all-time high of $13.34 billion, reached on December 31, 2021.
Performance
MRNA Free cash flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly FCF:
-$1.16B-$1.47B(-484.16%)Summary
- As of today (May 21, 2025), MRNA quarterly free cash flow is -$1.16 billion, with the most recent change of -$1.47 billion (-484.16%) on March 31, 2025.
- Over the past year, MRNA quarterly FCF has increased by +$21.00 million (+1.77%).
- MRNA quarterly FCF is now -128.86% below its all-time high of $4.03 billion, reached on June 30, 2021.
Performance
MRNA quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM FCF:
-$4.03B+$21.00M(+0.52%)Summary
- As of today (May 21, 2025), MRNA TTM free cash flow is -$4.03 billion, with the most recent change of +$21.00 million (+0.52%) on March 31, 2025.
- Over the past year, MRNA TTM FCF has dropped by -$362.00 million (-9.86%).
- MRNA TTM FCF is now -130.25% below its all-time high of $13.34 billion, reached on December 31, 2021.
Performance
MRNA TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Free cash flow Formula
FCF = Cash From Operations − CAPEX
MRNA Free cash flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -6.0% | +1.8% | -9.9% |
| 3 y3 years | -130.4% | -144.2% | -131.0% |
| 5 y5 years | -725.9% | -939.3% | -794.2% |
MRNA Free cash flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -130.4% | at low | -144.2% | +33.1% | -131.0% | +0.5% |
| 5 y | 5-year | -130.4% | at low | -128.9% | +33.1% | -130.3% | +0.5% |
| alltime | all time | -130.4% | at low | -128.9% | +33.1% | -130.3% | +0.5% |
MRNA Free cash flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$1.16B(-484.2%) | -$4.03B(-0.5%) |
| Dec 2024 | -$4.05B(+6.0%) | $303.00M(-117.6%) | -$4.05B(+2.5%) |
| Sep 2024 | - | -$1.72B(+17.9%) | -$3.96B(-0.6%) |
| Jun 2024 | - | -$1.46B(+22.9%) | -$3.98B(+8.4%) |
| Mar 2024 | - | -$1.19B(-394.8%) | -$3.67B(-4.0%) |
| Dec 2023 | -$3.83B(-183.5%) | $402.00M(-123.1%) | -$3.83B(+44.0%) |
| Sep 2023 | - | -$1.74B(+51.4%) | -$2.66B(+252.4%) |
| Jun 2023 | - | -$1.15B(-14.1%) | -$754.00M(-223.2%) |
| Mar 2023 | - | -$1.34B(-185.2%) | $612.00M(-86.6%) |
| Dec 2022 | $4.58B(-65.6%) | $1.57B(+863.2%) | $4.58B(-26.1%) |
| Sep 2022 | - | $163.00M(-24.9%) | $6.20B(-32.7%) |
| Jun 2022 | - | $217.00M(-91.8%) | $9.21B(-29.3%) |
| Mar 2022 | - | $2.63B(-17.5%) | $13.03B(-2.3%) |
| Dec 2021 | $13.34B(+580.8%) | $3.19B(+0.4%) | $13.34B(+17.1%) |
| Sep 2021 | - | $3.18B(-21.2%) | $11.39B(+25.4%) |
| Jun 2021 | - | $4.03B(+37.4%) | $9.08B(+81.4%) |
| Mar 2021 | - | $2.94B(+136.8%) | $5.01B(+155.6%) |
| Dec 2020 | $1.96B(-499.0%) | $1.24B(+41.9%) | $1.96B(+219.7%) |
| Sep 2020 | - | $874.00M(-2132.6%) | $612.84M(-263.4%) |
| Jun 2020 | - | -$43.00M(-61.6%) | -$374.97M(-16.9%) |
| Mar 2020 | - | -$112.00M(+5.5%) | -$451.14M(-8.1%) |
| Dec 2019 | -$491.00M(+12.5%) | -$106.16M(-6.7%) | -$491.00M(+0.3%) |
| Sep 2019 | - | -$113.80M(-4.5%) | -$489.50M(+1.5%) |
| Jun 2019 | - | -$119.17M(-21.5%) | -$482.04M(+8.3%) |
| Mar 2019 | - | -$151.86M(+45.1%) | -$445.20M(+2.0%) |
| Dec 2018 | -$436.63M(+12.0%) | -$104.66M(-1.6%) | -$436.63M(+31.4%) |
| Sep 2018 | - | -$106.35M(+29.2%) | -$332.31M(+46.9%) |
| Jun 2018 | - | -$82.33M(-42.5%) | -$226.23M(+56.5%) |
| Mar 2018 | - | -$143.29M(>+9900.0%) | -$144.57M(+8738.2%) |
| Dec 2017 | -$389.88M(-1260.7%) | -$337.50K(+27.0%) | -$1.64M(+7.3%) |
| Sep 2017 | - | -$265.70K(-60.3%) | -$1.52M(+17.7%) |
| Jun 2017 | - | -$668.50K(+83.7%) | -$1.30M(+83.3%) |
| Mar 2017 | - | -$364.00K(+60.9%) | -$706.50K(+35.2%) |
| Dec 2016 | $33.59M(-1619.9%) | - | - |
| Dec 2016 | - | -$226.20K(+518.0%) | -$522.40K(-38.8%) |
| Sep 2016 | - | -$36.60K(-54.1%) | -$854.20K(-35.6%) |
| Jun 2016 | - | -$79.70K(-55.7%) | -$1.33M(-21.2%) |
| Mar 2016 | - | -$179.90K(-67.8%) | -$1.68M(-22.3%) |
| Dec 2015 | -$2.21M(-53.8%) | -$558.00K(+9.8%) | -$2.17M(-28.0%) |
| Sep 2015 | - | -$508.00K(+16.2%) | -$3.01M(-16.7%) |
| Jun 2015 | - | -$437.00K(-34.0%) | -$3.61M(-17.5%) |
| Mar 2015 | - | -$662.00K(-52.8%) | -$4.38M(-8.4%) |
| Dec 2014 | -$4.78M(-1776.8%) | -$1.40M(+26.2%) | -$4.78M(+63.8%) |
| Sep 2014 | - | -$1.11M(-7.5%) | -$2.92M(+85.4%) |
| Jun 2014 | - | -$1.20M(+12.8%) | -$1.57M(+451.9%) |
| Mar 2014 | - | -$1.06M(-331.5%) | -$285.00K(-200.0%) |
| Dec 2013 | $285.00K(-106.5%) | $460.00K(+97.4%) | $285.00K(-133.9%) |
| Sep 2013 | - | $233.00K(+167.8%) | -$840.00K(-36.7%) |
| Jun 2013 | - | $87.00K(-117.6%) | -$1.33M(-22.4%) |
| Mar 2013 | - | -$495.00K(-25.6%) | -$1.71M(-61.1%) |
| Dec 2012 | -$4.39M(-72.8%) | -$665.00K(+162.8%) | -$4.39M(-22.3%) |
| Sep 2012 | - | -$253.00K(-14.2%) | -$5.65M(-44.4%) |
| Jun 2012 | - | -$295.00K(-90.7%) | -$10.16M(-31.3%) |
| Mar 2012 | - | -$3.18M(+65.3%) | -$14.79M(-8.3%) |
| Dec 2011 | -$16.12M(-6.3%) | -$1.92M(-59.7%) | -$16.12M(-5.5%) |
| Sep 2011 | - | -$4.76M(-3.2%) | -$17.05M(-2.8%) |
| Jun 2011 | - | -$4.92M(+9.1%) | -$17.54M(+2.1%) |
| Mar 2011 | - | -$4.51M(+58.1%) | -$17.18M(-0.2%) |
| Dec 2010 | -$17.20M(+125.8%) | -$2.85M(-45.7%) | -$17.20M(-4.9%) |
| Sep 2010 | - | -$5.26M(+15.2%) | -$18.08M(+2.5%) |
| Jun 2010 | - | -$4.56M(+0.6%) | -$17.65M(-8.7%) |
| Mar 2010 | - | -$4.54M(+21.6%) | -$19.34M(+153.8%) |
| Dec 2009 | -$7.62M | -$3.73M(-22.6%) | -$7.62M(-23.6%) |
| Sep 2009 | - | -$4.82M(-22.9%) | -$9.97M(-23.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2009 | - | -$6.25M(-187.0%) | -$12.97M(-24.6%) |
| Mar 2009 | - | $7.18M(-218.1%) | -$17.22M(-57.6%) |
| Dec 2008 | -$40.60M(-19.6%) | -$6.08M(-22.3%) | -$40.60M(-18.6%) |
| Sep 2008 | - | -$7.83M(-25.4%) | -$49.84M(-9.1%) |
| Jun 2008 | - | -$10.49M(-35.2%) | -$54.81M(-2.0%) |
| Mar 2008 | - | -$16.20M(+5.7%) | -$55.90M(+10.8%) |
| Dec 2007 | -$50.47M(+102.3%) | -$15.33M(+19.8%) | -$50.47M(+14.9%) |
| Sep 2007 | - | -$12.79M(+10.4%) | -$43.91M(+6.0%) |
| Jun 2007 | - | -$11.59M(+7.6%) | -$41.41M(+34.7%) |
| Mar 2007 | - | -$10.77M(+22.8%) | -$30.74M(+23.2%) |
| Dec 2006 | -$24.95M(-31.2%) | -$8.77M(-14.8%) | -$24.95M(+0.4%) |
| Sep 2006 | - | -$10.29M(+1025.9%) | -$24.85M(-4.3%) |
| Jun 2006 | - | -$914.00K(-81.7%) | -$25.96M(-22.7%) |
| Mar 2006 | - | -$4.98M(-42.5%) | -$33.58M(-7.4%) |
| Dec 2005 | -$36.24M(+69.9%) | -$8.67M(-23.9%) | -$36.24M(+35.3%) |
| Sep 2005 | - | -$11.40M(+33.5%) | -$26.79M(+20.1%) |
| Jun 2005 | - | -$8.54M(+11.6%) | -$22.30M(+9.5%) |
| Mar 2005 | - | -$7.65M(-1072.9%) | -$20.37M(-4.5%) |
| Dec 2004 | -$21.33M(+115.1%) | $786.00K(-111.4%) | -$21.33M(-26.7%) |
| Sep 2004 | - | -$6.91M(+4.6%) | -$29.11M(+1.5%) |
| Jun 2004 | - | -$6.60M(-23.3%) | -$28.67M(+7.1%) |
| Mar 2004 | - | -$8.61M(+23.1%) | -$26.77M(+170.0%) |
| Dec 2003 | -$9.91M(+11.8%) | -$7.00M(+8.1%) | -$9.91M(+16.6%) |
| Sep 2003 | - | -$6.47M(+37.5%) | -$8.50M(+58.9%) |
| Jun 2003 | - | -$4.70M(-157.0%) | -$5.35M(+2601.5%) |
| Mar 2003 | - | $8.25M(-247.8%) | -$198.00K(-97.8%) |
| Dec 2002 | -$8.87M(+18.0%) | -$5.58M(+68.4%) | -$8.87M(+37.1%) |
| Sep 2002 | - | -$3.31M(-841.6%) | -$6.47M(+61.9%) |
| Jun 2002 | - | $447.00K(-207.2%) | -$4.00M(-37.1%) |
| Mar 2002 | - | -$417.00K(-86.9%) | -$6.35M(-15.5%) |
| Dec 2001 | -$7.51M(-11.2%) | -$3.18M(+276.9%) | -$7.51M(+25.7%) |
| Sep 2001 | - | -$844.00K(-55.7%) | -$5.97M(-14.6%) |
| Jun 2001 | - | -$1.91M(+20.6%) | -$7.00M(+14.4%) |
| Mar 2001 | - | -$1.58M(-3.8%) | -$6.12M(-27.6%) |
| Dec 2000 | -$8.46M(+1.9%) | -$1.64M(-12.0%) | -$8.46M(-14.7%) |
| Sep 2000 | - | -$1.87M(+82.5%) | -$9.91M(-2.3%) |
| Jun 2000 | - | -$1.02M(-73.9%) | -$10.14M(-7.1%) |
| Mar 2000 | - | -$3.92M(+26.4%) | -$10.92M(+31.5%) |
| Dec 1999 | -$8.30M(+159.4%) | -$3.10M(+47.6%) | -$8.30M(+38.3%) |
| Sep 1999 | - | -$2.10M(+16.7%) | -$6.00M(+46.3%) |
| Jun 1999 | - | -$1.80M(+38.5%) | -$4.10M(+46.4%) |
| Mar 1999 | - | -$1.30M(+62.5%) | -$2.80M(-12.5%) |
| Dec 1998 | -$3.20M(-15.8%) | -$800.00K(+300.0%) | -$3.20M(-3.0%) |
| Sep 1998 | - | -$200.00K(-60.0%) | -$3.30M(-23.3%) |
| Jun 1998 | - | -$500.00K(-70.6%) | -$4.30M(-10.4%) |
| Mar 1998 | - | -$1.70M(+88.9%) | -$4.80M(+26.3%) |
| Dec 1997 | -$3.80M(+442.9%) | -$900.00K(-25.0%) | -$3.80M(+31.0%) |
| Sep 1997 | - | -$1.20M(+20.0%) | -$2.90M(+26.1%) |
| Jun 1997 | - | -$1.00M(+42.9%) | -$2.30M(+130.0%) |
| Mar 1997 | - | -$700.00K(+16.7%) | -$1.00M(+66.7%) |
| Dec 1996 | -$700.00K(<-9900.0%) | - | - |
| Sep 1996 | - | -$600.00K(-300.0%) | -$600.00K(<-9900.0%) |
| Jun 1996 | $0.00(0.0%) | $300.00K(-400.0%) | $0.00(-100.0%) |
| Mar 1996 | - | -$100.00K(-50.0%) | -$300.00K(+50.0%) |
| Dec 1995 | - | -$200.00K(<-9900.0%) | -$200.00K(<-9900.0%) |
| Sep 1995 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Jun 1995 | $0.00(-100.0%) | $0.00(0.0%) | $100.00K(0.0%) |
| Mar 1995 | - | $0.00(0.0%) | $100.00K(-200.0%) |
| Dec 1994 | - | $0.00(-100.0%) | -$100.00K(-200.0%) |
| Sep 1994 | - | $100.00K(>+9900.0%) | $100.00K(0.0%) |
| Jun 1994 | $100.00K | $0.00(-100.0%) | $100.00K(0.0%) |
| Mar 1994 | - | -$200.00K(-200.0%) | $100.00K(-66.7%) |
| Dec 1993 | - | $200.00K(+100.0%) | $300.00K(+200.0%) |
| Sep 1993 | - | $100.00K | $100.00K |
FAQ
- What is Moderna annual free cash flow?
- What is the all time high annual FCF for Moderna?
- What is Moderna annual FCF year-on-year change?
- What is Moderna quarterly free cash flow?
- What is the all time high quarterly FCF for Moderna?
- What is Moderna quarterly FCF year-on-year change?
- What is Moderna TTM free cash flow?
- What is the all time high TTM FCF for Moderna?
- What is Moderna TTM FCF year-on-year change?
What is Moderna annual free cash flow?
The current annual FCF of MRNA is -$4.05B
What is the all time high annual FCF for Moderna?
Moderna all-time high annual free cash flow is $13.34B
What is Moderna annual FCF year-on-year change?
Over the past year, MRNA annual free cash flow has changed by -$230.00M (-6.01%)
What is Moderna quarterly free cash flow?
The current quarterly FCF of MRNA is -$1.16B
What is the all time high quarterly FCF for Moderna?
Moderna all-time high quarterly free cash flow is $4.03B
What is Moderna quarterly FCF year-on-year change?
Over the past year, MRNA quarterly free cash flow has changed by +$21.00M (+1.77%)
What is Moderna TTM free cash flow?
The current TTM FCF of MRNA is -$4.03B
What is the all time high TTM FCF for Moderna?
Moderna all-time high TTM free cash flow is $13.34B
What is Moderna TTM FCF year-on-year change?
Over the past year, MRNA TTM free cash flow has changed by -$362.00M (-9.86%)